Clinical Trials Logo

Clinical Trial Summary

A randomized prospective study of the evaluation of the clinical IVF results after following Long Antagonist protocol for controlled ovarian stimulation versus following classical antagonist protocol


Clinical Trial Description

A randomized prospective study of administration of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF: Single dose of Degarelix (24mg, 16mg or 12 mg), on day 24th of previous luteal face cycle, was administered. The Clinical Pregnancy and Live Birth Rates were estimated for this group of patients, comparing to the rates of the group which followed classical antagonist protocol. The number of the formed blastocysts in each group is measured, as well. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03684421
Study type Observational
Source Assisting Nature
Contact Evaggelos Papanikolaou, MD,PhD
Phone 00302310424294
Email drvagpapanikolaou@yahoo.gr
Status Recruiting
Phase
Start date February 15, 2017
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03463278 - The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
Completed NCT02442895 - Biomarkers of Ovarian Reserve and Correlation With IVF Treatments N/A
Completed NCT00773825 - Genomic Imprinting and Assisted Reproductive Technologies N/A
Recruiting NCT03693534 - Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol
Recruiting NCT03240159 - Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix Phase 3